GlassScriptPhysician profile
Nabeel Omar
NPI 1306627427
$2,524.92
in general payments reported to CMS, 2019-2025
28 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.14 · 2024: $994 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,524.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $348.20 | 2024-2025 | Ibsrela |
| Abbvie INC. | $287.55 | 2024-2025 | |
| Novo Nordisk INC | $242.17 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $232.22 | 2024-2025 | Rexulti |
| Amgen INC. | $189.32 | 2024-2025 | Krystexxa, Repatha |
| Ironwood Pharmaceuticals, INC | $113.69 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $104.18 | 2024-2025 | Airsupra |
| Glaxosmithkline, LLC. | $99.22 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Indivior INC. | $91.87 | 2024-2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.21 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $84.51 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $73.40 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $65.86 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $64.97 | 2024-2025 | Zenpep |
| Forte Bio-Pharma LLC | $59.84 | 2025 | Prolate, Nalocet, Tanlor |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $56.72 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.07 | 2024-2025 | Caplyta |
| Cipher Pharmaceuticals US LLC | $41.18 | 2025 | Spinosad, Natroba |
| Orexo US, INC. | $36.94 | 2024 | Zubsolv |
| Lundbeck LLC | $36.22 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $27.87 | 2024 | Austedo Xr |
| Gilead Sciences, INC. | $22.66 | 2025 | |
| Viatris Specialty LLC | $20.69 | 2025 | Yupelri |
| Sumitomo Pharma America, INC. | $20.61 | 2024 | Gemtesa |
| Collegium Pharmaceutical, INC. | $18.14 | 2023 | Xtampza |
| Actelion Pharmaceuticals US, INC. | $16.61 | 2025 | Opsumit, Uptravi |
| Lilly USA, LLC | $16.19 | 2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $15.81 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabeel Omar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.